

1. 1. Atomic Industrial Estate
Mumbai - 400 015
Andhra Pradesh, India
Mumbai - 400 015
Mumbai - 400 015

SUN PHARMA
ADVANCED RESEARCH
COMPANY LTD.

10 April 2012.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.


Dear Sirs,

Sub: Press Release

We are pleased to enclose herewith our Press Release relating to the Starhaler® Device finalist at Medical Design Excellence Awards, which we shall be releasing after faxing this letter to you. This is for your information and record.

Thanking you,

Yours faithfully,
For Sun Pharma Advanced Research Company Ltd.


Meetal Sampat
Company Secretary

Encl: as above

Sun Pharma Industrial Estate
 Marolli, Sector 12, Marolli
 Andheri East, Mumbai-400 059, India
 Tel: +91 22 66455685
 Fax: +91 22 66455686

SUN PHARMA
 ADVANCED RESEARCH
 COMPANY LTD.

FOR IMMEDIATE RELEASE

Starhaler® Device finalist at Medical Design Excellence Awards

Mumbai, April 10, 2012: SPARC Ltd's Combitide Starhaler® for asthma and COPD is a finalist at the 2012 Medical Design Excellence Awards (MDEA) to be held in Philadelphia this May.

MDEA is the premier awards program for the medical technology community, and the only awards program that exclusively recognizes contributions and advances in the design of medical products.

Combitide Starhaler® is a novel, high performance multi dose dry powder Inhaler. This next generation DPI improves on current marketed devices.

The inhaler has a uniform delivery profile that ensures that the full intended metered dose of the drug is administered to the deep lung, regardless of the strength of the patient's intake of breath. This step change in inhaler technology offers a reliable and easy to use device, particularly for patients with impaired lung function.

Similar therapeutic benefit to the marketed devices was achieved while only using half the amount of drug. This reduced drug usage offer significant benefits to patients, over the side effects associated with many asthma and COPD therapies.

In addition, the device integrates a number of user-friendly design features. These include: a numerical dose counter to indicate at a glance how many more doses are left in the Inhaler before it runs out, a luminous feature to enable users to find the device in the dark, and a small pop-out 'braille' button which activates when there are only a few doses remaining. The device also features a unique palm-held form, designed to discreetly house the complex dose carriage and delivery system, yet remain comfortable to hold and use.

Combitide Starhaler® has been introduced in the Indian market last year by Sun Pharmaceutical Industries Ltd.

About SPARC

Sun Pharma Advanced Research Company Ltd (NSE: SPARC, BSE: 532872) is an international pharmaceutical company engaged in research and development of drugs and delivery systems. More information about the company can be found at www.sunpharma.in.

"The Company is proposing, subject to market conditions and other considerations, rights issue of its equity shares and the Company has filed a Draft Letter of Offer with the Stock Exchanges and the Securities and Exchange Board of India ("SEBI"). The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the website of the Lead Manager at <http://www.ey.com/IN/en/Services/Transactions>. Any potential investor should note that investment in equity shares involves a high degree of risk. For details, see the section titled "Risk Factors" of the Draft Letter of Offer."

About the Award

The award is based upon descriptive materials submitted to the jurors; the jurors and the competition operators did not verify the accuracy of any submission or of any claims made and did not test the item to which the award was given.

Entries for the MDEA are evaluated on the basis of their design, engineering features, innovative use of materials, user-related functions that improve healthcare delivery, features that provide enhanced patient benefits, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.

111, Mahabharat state
Mumbai 400 001, India
Tel: +91 22 6645 5645
Fax: +91 22 6645 5685

SUN PHARMA
ADVANCED RESEARCH
COMPANY LTD.

Contact

Uday Baldota

Tel +91 22 6645 5645, Ext 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai

Tel +91 22 6645 5645, Ext 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail miradesai@sunpharma.com

All trademarks belong to respective owners.